Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

SEOM clinical guidelines in early stage breast cancer (2018).

Ayala de la Peña F, Andrés R, Garcia-Sáenz JA, Manso L, Margelí M, Dalmau E, Pernas S, Prat A, Servitja S, Ciruelos E.

Clin Transl Oncol. 2018 Nov 15. doi: 10.1007/s12094-018-1973-6. [Epub ahead of print]

PMID:
30443868
2.

Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer.

Manso L, Sanchez-Muñoz A, Calvo I, Izarzugaza Y, Plata J, Rodriguez C.

Breast Care (Basel). 2018 Aug;13(4):277-283. doi: 10.1159/000488794. Epub 2018 Jul 13. Review.

3.

Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study.

Redondo A, Ramos Vázquez M, Manso L, Gil Gil MJ, Garau Llinas I, García-Garre E, Rodríguez CA, Chacón JI, López-Vivanco G.

Onco Targets Ther. 2018 Sep 17;11:5845-5852. doi: 10.2147/OTT.S170303. eCollection 2018.

4.

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer.

Zagorac I, Fernandez-Gaitero S, Penning R, Post H, Bueno MJ, Mouron S, Manso L, Morente MM, Alonso S, Serra V, Muñoz J, Gómez-López G, Lopez-Acosta JF, Jimenez-Renard V, Gris-Oliver A, Al-Shahrour F, Piñeiro-Yañez E, Montoya-Suarez JL, Apala JV, Moreno-Torres A, Colomer R, Dopazo A, Heck AJR, Altelaar M, Quintela-Fandino M.

Nat Commun. 2018 Aug 29;9(1):3501. doi: 10.1038/s41467-018-05742-z.

5.

Microbiome and Allergic Diseases.

Pascal M, Perez-Gordo M, Caballero T, Escribese MM, Lopez Longo MN, Luengo O, Manso L, Matheu V, Seoane E, Zamorano M, Labrador M, Mayorga C.

Front Immunol. 2018 Jul 17;9:1584. doi: 10.3389/fimmu.2018.01584. eCollection 2018. Review.

6.

Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.

Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C.

Gynecol Oncol. 2018 Sep;150(3):471-477. doi: 10.1016/j.ygyno.2018.07.018. Epub 2018 Jul 27.

7.

A Spiking Neural Model of HT3D for Corner Detection.

Bachiller-Burgos P, Manso LJ, Bustos P.

Front Comput Neurosci. 2018 Jun 1;12:37. doi: 10.3389/fncom.2018.00037. eCollection 2018.

8.

Exosomes: Definition, Role in Tumor Development and Clinical Implications.

Carretero-González A, Otero I, Carril-Ajuria L, de Velasco G, Manso L.

Cancer Microenviron. 2018 Jun;11(1):13-21. doi: 10.1007/s12307-018-0211-7. Epub 2018 May 3. Review.

9.

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J.

Lancet Oncol. 2018 Jun;19(6):812-824. doi: 10.1016/S1470-2045(18)30147-5. Epub 2018 Apr 26.

PMID:
29706375
10.

Special issue on cognitive robotics.

Bandera A, Dias J, Vincze M, Manso LJ.

Cogn Process. 2018 May;19(2):231-232. doi: 10.1007/s10339-018-0863-8. Epub 2018 Apr 16. No abstract available.

PMID:
29658054
11.

Mixed cropping regimes promote the soil fungal community under zero tillage.

Silvestro LB, Biganzoli F, Stenglein SA, Forjan H, Manso L, Moreno MV.

Antonie Van Leeuwenhoek. 2018 Jul;111(7):1055-1064. doi: 10.1007/s10482-017-1005-5. Epub 2017 Dec 21.

PMID:
29270767
12.

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.

Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E.

Ann Oncol. 2018 Jan 1;29(1):170-177. doi: 10.1093/annonc/mdx647.

PMID:
29045543
13.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A.

J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.

PMID:
28968163
14.

Integrating planning perception and action for informed object search.

Manso LJ, Gutierrez MA, Bustos P, Bachiller P.

Cogn Process. 2018 May;19(2):285-296. doi: 10.1007/s10339-017-0828-3. Epub 2017 Aug 14.

PMID:
28808825
15.

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.

Pascual T, Apellániz-Ruiz M, Pernaut C, Cueto-Felgueroso C, Villalba P, Álvarez C, Manso L, Inglada-Pérez L, Robledo M, Rodríguez-Antona C, Ciruelos E.

PLoS One. 2017 Jul 20;12(7):e0180192. doi: 10.1371/journal.pone.0180192. eCollection 2017.

16.

Validation of the Spanish Version of the Food Allergy Quality of Life Questionnaire-Parent Form (S-FAQLQ-PF).

Manso L, Pineda R, Huertas B, Fernández-Rivas M, Diéguez MC, Cerecedo I, Muriel A, Fernández FB, DunnGalvin A, Antolín-Amérigo D, De la Hoz B.

J Investig Allergol Clin Immunol. 2017;27(6):363-369. doi: 10.18176/jiaci.0182. Epub 2017 Jun 28.

17.

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.

Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, González-Rivera M, Galván P, Zalfa F, Amato M, Gonzalez L, Prats M, Rojo F, Manso L, Paré L, Alonso I, Albanell J, Vivancos A, González A, Matito J, González S, Fernandez P, Adamo B, Muñoz M, Viladot M, Font C, Aya F, Vidal M, Caballero R, Carrasco E, Altomare V, Tonini G, Prat A, Martin M.

Oncotarget. 2017 Mar 28;8(13):21930-21937. doi: 10.18632/oncotarget.15748.

18.

Critically short telomeres and toxicity of chemotherapy in early breast cancer.

Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA.

Oncotarget. 2017 Mar 28;8(13):21472-21482. doi: 10.18632/oncotarget.15592.

19.

A Passive Learning Sensor Architecture for Multimodal Image Labeling: An Application for Social Robots.

Gutiérrez MA, Manso LJ, Pandya H, Núñez P.

Sensors (Basel). 2017 Feb 11;17(2). pii: E353. doi: 10.3390/s17020353.

20.

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.

Quintela-Fandino M, Lluch A, Manso L, Calvo I, Cortes J, García-Saenz JA, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Guerra J, Bermejo B, Zamora E, Moreno-Anton F, Pernas Simon S, Carrato A, Lopez-Alonso A, Escudero MJ, Campo R, Carrasco E, Palacios J, Mulero F, Colomer R.

Clin Cancer Res. 2017 Mar 15;23(6):1432-1441. doi: 10.1158/1078-0432.CCR-16-0738. Epub 2016 Sep 1.

21.

Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.

Manso L, Mourón S, Tress M, Gómez-López G, Morente M, Ciruelos E, Rubio-Camarillo M, Rodriguez-Peralto JL, Pujana MA, Pisano DG, Quintela-Fandino M.

PLoS One. 2016 May 19;11(5):e0155840. doi: 10.1371/journal.pone.0155840. eCollection 2016.

22.

Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases.

Laimito KR, Gámez-Pozo A, Sepúlveda J, Manso L, López-Vacas R, Pascual T, Fresno Vara JA, Ciruelos E.

Ecancermedicalscience. 2016 Apr 11;10:632. doi: 10.3332/ecancer.2016.632. eCollection 2016. Review.

23.

Quality of life in patients with food allergy.

Antolín-Amérigo D, Manso L, Caminati M, de la Hoz Caballer B, Cerecedo I, Muriel A, Rodríguez-Rodríguez M, Barbarroja-Escudero J, Sánchez-González MJ, Huertas-Barbudo B, Alvarez-Mon M.

Clin Mol Allergy. 2016 Feb 17;14:4. doi: 10.1186/s12948-016-0041-4. eCollection 2016. Review.

24.

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.

Manso L, Palomo AG, Pérez Carrión R, Cassinello J, Gallegos Sancho I, Chacón López-Muñiz I, Olier C, Fernández-Aramburo A, Llorca C, González X, Llorente R, Torregrosa D, Álvarez I, Gálve E, Bueno C, Garau I, García MJ, González-Santiago S, Ballesteros AI, Blanco E, Galán A, González S, Perelló A, Cortés-Funes H, Grávalos C.

Anticancer Res. 2015 Dec;35(12):6941-50.

PMID:
26637920
25.

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J.

Breast Cancer Res Treat. 2015 Nov;154(2):351-7. doi: 10.1007/s10549-015-3616-8. Epub 2015 Nov 4.

26.

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.

Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C, Garcia-Martínez E, Martinez-Jáñez N, Melé M, Llombart A, Pernas S, Villagrasa P, Blasco C, Baselga J.

Breast Cancer Res Treat. 2015 Jun;151(3):597-606. doi: 10.1007/s10549-015-3415-2. Epub 2015 May 16.

PMID:
25981896
27.

The need for post-mastectomy radiotherapy in patients with IBC.

Ares GR, Ciruelos E, Manso L.

Nat Rev Clin Oncol. 2015 Jun;12(6):370. doi: 10.1038/nrclinonc.2015.13-c1. Epub 2015 Apr 28. No abstract available.

PMID:
25917250
28.

Use of bevacizumab as a first-line treatment for metastatic breast cancer.

Manso L, Moreno F, Márquez R, Castelo B, Arcediano A, Arroyo M, Ballesteros AI, Calvo I, Echarri MJ, Enrech S, Gómez A, González Del Val R, López-Miranda E, Martín-Angulo M, Martínez-Jañez N, Olier C, Zamora P.

Curr Oncol. 2015 Apr;22(2):e51-60. doi: 10.3747/co.22.2210.

29.

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.

Martín M, González-Rivera M, Morales S, de la Haba-Rodriguez J, González-Cortijo L, Manso L, Albanell J, González-Martín A, González S, Arcusa A, de la Cruz-Merino L, Rojo F, Vidal M, Galván P, Aguirre E, Morales C, Ferree S, Pompilio K, Casas M, Caballero R, Goicoechea U, Carrasco E, Michalopoulos S, Hornberger J, Prat A.

Curr Med Res Opin. 2015 Jun;31(6):1129-37. doi: 10.1185/03007995.2015.1037730. Epub 2015 Apr 23.

PMID:
25851308
30.

Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.

Sotelo MJ, García-Sáenz JA, Manso L, Moreno F, Ciruelos E, Callata HR, Mendiola C, Cabezas S, Ghanem I, Díaz-Rubio E.

J Cancer Res Ther. 2014 Oct-Dec;10(4):967-72. doi: 10.4103/0973-1482.138017.

31.

Bioregulation of kallikrein-related peptidases 6, 10 and 11 by the kinin B₁ receptor in breast cancer cells.

Ehrenfeld P, Manso L, Pavicic MF, Matus CE, Borquez C, Lizama A, Sarmiento J, Poblete MT, Bhoola KD, Naran A, Figueroa CD.

Anticancer Res. 2014 Dec;34(12):6925-38.

PMID:
25503118
32.

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

Gámez-Pozo A, Pérez Carrión RM, Manso L, Crespo C, Mendiola C, López-Vacas R, Berges-Soria J, López IÁ, Margeli M, Calero JL, Farre XG, Santaballa A, Ciruelos EM, Afonso R, Lao J, Catalán G, Gallego JV, López JM, Bofill FJ, Borrego MR, Espinosa E, Vara JA, Zamora P.

PLoS One. 2014 Oct 20;9(10):e109611. doi: 10.1371/journal.pone.0109611. eCollection 2014.

33.

THERAPIST: Towards an Autonomous Socially Interactive Robot for Motor and Neurorehabilitation Therapies for Children.

Calderita LV, Manso LJ, Bustos P, Suárez-Mejías C, Fernández F, Bandera A.

JMIR Rehabil Assist Technol. 2014 Oct 7;1(1):e1. doi: 10.2196/rehab.3151.

34.

Evolution of occupational asthma: does cessation of exposure really improve prognosis?

Munoz X, Viladrich M, Manso L, del Pozo V, Quirce S, Cruz MJ, Carmona F, Sánchez-Pla A, Sastre J.

Respir Med. 2014 Sep;108(9):1363-70. doi: 10.1016/j.rmed.2014.08.001. Epub 2014 Aug 14.

35.

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.

Salvador J, Manso L, de la Haba J, Jaen A, Ciruelos E, de Villena MC, Gil M, Murias A, Galan A, Jara C, Bayo J, Baena JM, Casal J, Mel JR, Blancas I, Sanchez Rvira P.

Clin Transl Oncol. 2015 Feb;17(2):160-6. doi: 10.1007/s12094-014-1210-x. Epub 2014 Aug 14.

PMID:
25119930
36.

Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).

Barnadas A, Manso L, de la Piedra C, Meseguer C, Crespo C, Gómez P, Calvo L, Martinez P, Ruiz-Borrego M, Perelló A, Antón A, Codes M, Margelí M, Murias A, Salvador J, Seguí MÁ, de Juan A, Gavilá J, Luque M, Pérez D, Zamora P, Arizcuma A, Chacón JI, Heras L, Martin-Fernández M, Mahillo-Fernández I, Tusquets I.

Bone. 2014 Nov;68:32-40. doi: 10.1016/j.bone.2014.07.036. Epub 2014 Aug 7.

PMID:
25108081
37.

Allergy to short-acting β2-agonists in a COPD patient: Is an immunological mechanism involved?

Manso L, Valbuena T, Padial MA, Reche M, Zafra MP, Del Pozo V, Pascual CY.

Allergol Immunopathol (Madr). 2015 May-Jun;43(3):329-30. doi: 10.1016/j.aller.2014.04.003. Epub 2014 Aug 3. No abstract available.

PMID:
25097024
38.

European inter-institutional impact study of MammaPrint.

Cusumano PG, Generali D, Ciruelos E, Manso L, Ghanem I, Lifrange E, Jerusalem G, Klaase J, de Snoo F, Stork-Sloots L, Dekker-Vroling L, Lutke Holzik M.

Breast. 2014 Aug;23(4):423-8. doi: 10.1016/j.breast.2014.02.011. Epub 2014 Mar 28.

PMID:
24685596
39.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S.

Lancet Oncol. 2014 Apr;15(4):406-14. doi: 10.1016/S1470-2045(14)70069-5. Epub 2014 Mar 11.

PMID:
24636208
40.

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, Muñoz C, Vega E, Calderón MJ, Sancho B, Cortes-Funes H.

Breast. 2014 Jun;23(3):201-8. doi: 10.1016/j.breast.2014.01.016. Epub 2014 Mar 1. Review.

41.

Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.

Zamorano-León JJ, Olivier C, de Las Heras N, Mateos-Cáceres PJ, Brime Menéndez R, Rodríguez-Sierra P, Martín Palacios N, Manso LS, Modrego J, Segura A, Macaya C, López-Farré AJ.

J Sex Med. 2013 Dec;10(12):3110-20. doi: 10.1111/jsm.12324. Epub 2013 Sep 24.

PMID:
24112450
42.

Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.

Ciruelos E, Cortes-Funes H, Ghanem I, Manso L, Arteaga C.

Anticancer Drugs. 2013 Sep;24(8):769-80. doi: 10.1097/CAD.0b013e328363adc5. Review.

PMID:
23838677
43.

Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.

Manso L, Valdiviezo N, Sepúlveda J, Ciruelos E, Mendiola C, Ghanem I, Vega E, Manneh R, Dorta M, Cortés-Funes H.

Clin Transl Oncol. 2013 Jun;15(6):467-71. doi: 10.1007/s12094-012-0954-4. Epub 2012 Dec 21.

PMID:
23263907
44.

Diagnostic tools assessing airway remodelling in asthma.

Manso L, Reche M, Padial MA, Valbuena T, Pascual C.

Allergol Immunopathol (Madr). 2012 Mar-Apr;40(2):108-16. doi: 10.1016/j.aller.2011.11.002. Epub 2012 Jan 9. Review.

PMID:
22236733
45.

Medical and economic impact of misdiagnosis of drug hypersensitivity in hospitalized patients.

Sastre J, Manso L, Sanchez-García S, Fernández-Nieto M.

J Allergy Clin Immunol. 2012 Feb;129(2):566-7. doi: 10.1016/j.jaci.2011.09.028. Epub 2011 Oct 27. No abstract available.

PMID:
22035657
46.
47.

Comparison of bronchial hyperresponsiveness to methacholine and adenosine and airway inflammation markers in patients with suspected asthma.

Manso L, Madero MF, Ruiz-García M, Fernández-Nieto M, Sastre J.

J Asthma. 2011 May;48(4):335-40. doi: 10.3109/02770903.2011.565850.

PMID:
21504347
48.

Basophil activation test in a case of systemic hypersensitivity reaction to infliximab with good tolerance to another anti-TNF-alpha agent (adalimumab).

Manso L, Polo B, Fernández-Nieto M, Sastre LB, del Pozo V, Sastre J.

J Investig Allergol Clin Immunol. 2010;20(6):537-8. No abstract available.

49.

Occupational asthma caused by triglycidyl isocyanurate.

Sastre J, Carnes J, García del Potro M, Manso L, Aguado E, Fernández-Nieto M.

Int Arch Occup Environ Health. 2011 Jun;84(5):547-9. doi: 10.1007/s00420-010-0570-y. Epub 2010 Aug 18.

PMID:
20717691
50.

Cross-reactivity between coconut and lentil related to a 7S globulin and an 11S globulin.

Manso L, Pastor C, Pérez-Gordo M, Cases B, Sastre J, Cuesta-Herranz J.

Allergy. 2010 Nov;65(11):1487-8. doi: 10.1111/j.1398-9995.2010.02370.x. No abstract available.

PMID:
20415717

Supplemental Content

Support Center